<DOC>
	<DOCNO>NCT00203879</DOCNO>
	<brief_summary>Purpose investigation : Primary hypothesis : Immunization patient 4 melanoma antigen peptide induce augment specific IFN-y-producing CD8+ T cell 4 antigen simultaneously . Immunization 4 melanoma antigen peptide increase response rate 10 % 30 % . Administration low-dose IL-2 follow vaccine result great 3-fold increase specific T cell compare IL-2 . Secondary hypothesis : Immunization clear blood detectable circulate melanoma cell . Tumors grow despite induction melanoma antigen-specific T cell may lack expression antigen , class I MHC , TAP peptide transporter , may fail show increased expression mRNA IFN-y perforin . Tumors resist vaccination may express different array gene susceptible vaccination .</brief_summary>
	<brief_title>Study MAGE-3/Melan-A/gp 100/NA17 rhIL-12 With/Out Low Dose IL-2 Metastatic Melanoma</brief_title>
	<detailed_description>Based preclinical Phase I result , logical strategy second generation melanoma vaccine emerge . A randomized Phase II study metastatic melanoma patient undertaken . Patients first HLA-typed ; HLA-A2-positive patient eligible screen . When feasible , patient undergo tumor biopsy screen expression MAGE-3 , Melan-A , gplOO , NAI 7 use RT-PCR immunohistochemistry , determine whether T cell present lesion , measure cytokine gene expression RT-PCR , perform gene array analysis . In addition , blood cell analyze certain parameter T cell function . Patients randomize cohort A ( IL-2 ) B ( low-dose IL-2 ) . For treatment , peripheral blood collect fractionated density centrifugation isolate PBMC source APC . The PBMC divide four pool , incubate one follow peptide : MAGE-3 , Melan-A , gp 100 , Ni 7A . The peptide-loaded cell wash recombine single suspension PBS , lethally irradiate . Approximately 120 x 106 pulsed cell inject subcutaneously site near lymph node think involved tumor . The subcutaneous route select reason safety , efficacy preclinical model , goal target vaccine drain lymph node . rhIL-12 ( 4 .tg straight dose ) give subcutaneously adjacent vaccine site day 1,3 , 5 cycle . This dose schedule find effective phase I study . In one-half patient ( cohort B ) , IL-2 ( I MU straight dose ) administer subcutaneously daily , day 7-18 . Re-immunization along rhIL-12 follow IL-2 ( assign ) perform 3 week interval cycle I . On day 1 cycle , peripheral blood collect measure peptide-specific IFN-y production . Before treatment every 3 cycle , PBMC collect quantify peptide specific CD8 T cell flow cytometric analysis peptide/HLA-A2 tetramers , evidence molecular response assess perform RT-PCR . melanoma antigens peripheral blood sample . In addition , prior treatment , first 3 cycle , time go off- study , tumor biopsy perform assess immune response tumor microenvironment , include gene array analysis . It hop study uncover reason lack clinical response patient residual tumor . Clinical response assess secondary outcome .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Histologicallyconfirmed melanoma evidence metastatic disease , either radiologic physical examination . In transit metastasis allow . Biopsy perform reconfirm diagnosis case doubt . Life expectancy least 12 week . Karnofsky performance status index &gt; /=70 . Written inform consent Adequate hematopoietic , renal , hepatic function LDH &lt; 1.25 x ULN HLA typing : patient must express HLAA2 . Tumor biopsy : patient must agree undergo biopsy accessible tumor therapy , feasible , study tumor cell property characteristics immune cell . Significant cardiovascular disease , cardiac arrhythmia require medical intervention . Pregnant nursing woman . Biological therapy 4 week prior start dose . Prior therapy melanoma vaccine contain MAGE3 , MelanA , gplOO , NA17 peptide . Patients intrinsic immunosuppression , include seropositivity HIV antibody . Patient test risk factor identify . Serious concurrent infection , include active tuberculosis , hepatitis B , hepatitis C. Concurrent systemic corticosteroid ( except physiologic replacement dos ) immunosuppressive drug ( eg . cyclosporin A ) . Psychiatric illness may make compliance clinical protocol unmanageable may compromise ability patient give inform consent . Active history autoimmune disease include limited : rheumatoid arthritis ( RFpositive current recent flare ) , inflammatory bowel disease , systemic lupus erythematosis ( clinical evidence ANA 1:80 great ) , ankylose spondylitis , scleroderma , multiple sclerosis , autoimmune hemolytic anemia , immune thrombocytopenic purpura . Active gastrointestinal bleeding uncontrolled peptic ulcer disease . Presence untreated brain metastasis . All patient must undergo brain image part prestudy evaluation . Only patient brain metastasis , brain lesion successfully treat stereotactic radiation surgical removal without recurrence 28 day followup , eligible .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>metastatic melanoma</keyword>
</DOC>